We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Syncona Limited (SYNC) Ordinary NPV

Sell:122.60p Buy:124.00p 0 Change: 1.20p (0.98%)
FTSE 250:0.21%
Market closed Prices as at close on 28 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:122.60p
Buy:124.00p
Change: 1.20p (0.98%)
Market closed Prices as at close on 28 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:122.60p
Buy:124.00p
Change: 1.20p (0.98%)
Market closed Prices as at close on 28 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Objective

To achieve superior long-term capital appreciation from its investments. The Company invests in life science businesses and single or multi-asset projects. The Company will target an IRR per share across its investment portfolio of 15% p.a. over the long term. Over time, it is intended that the Company should invest the significant majority of its assets in Life Science Investments.
Security Weight
Uk Treasury Bills 13.50%
Capital Pool Investment Funds 7.46%
Quell Therapeutics Limited 6.11%
Swan Bio Therapeutics Limited 5.63%
Autolus Therapeutics PLC ADR 4.65%
Anaveon Ag 4.49%
Milestone Payments 3.74%
Legacy Funds 2.99%
O Mass Therapeutics Limited 2.60%
Freeline Therapeutics Holdings PLC ADR 2.42%

Top 10 sectors currently unavailable.

Country Weight
United Kingdom 8.93%

Fee Structure

The company will pay SIML an annual fee of up to 1.05% p.a. of the NAV of company. The fee will be payable monthly in arrears and each payment shall be calculated using the monthly NAV as at the relevant month end.

Dividend Policy

The Company has announced that it does not intend to pay an annual dividend in future years.

ASSET SPLIT

Total number of holdings: 19.

Trust Manager

Not currently available for this investment trust.

Manager Bio

Not currently available for this investment trust.

Board Of Directors

Melanie GeeChairman, Virginia Holmes, Cristina Csimma, Julie Cherrington, Gian Reverberi, Kemal Malik, Robert Hutchinson

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.